ESMO 2025: Discussant – A Phase III Study of Capivasertib + Abiraterone ...
ESMO 2025: A Phase III Study of Capivasertib + Abiraterone versus ...
ESMO 2025: Discussant – Phase III Trial of [177Lu]Lu-PSMA-617 Combined ...
#IPATential150: phase III study of ipatasertib + abiraterone vs pbo ...
ESMO 2025: Phase III Trial of [177Lu]Lu-PSMA-617 Combined with ADT ...
ESMO 2025: Discussant: Randomized Phase III Trial of Androgen ...
ASCO 2024: CYCLONE 2: A Phase 3 study of Abemaciclib with Abiraterone ...
ESMO 2025: Randomized Phase III Trial of Androgen Deprivation Therapy ...
ESMO Virtual Congress 2020: IPATential150: Phase III Study of ...
ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate ...
ESMO 2025: Final Results from PRESTO (AFT-19): A Phase 3 Open-label ...
Analysis of the phase III #CAPItello281 trial: Capivasertib ...
HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and ...
ESMO 2025: Prevalence and Severity of Hot Flashes and Their Association ...
ESMO 2025: Discussant – EMBARK and PRESTO Trials
ASCO 2025: Phase 3 AMPLITUDE Trial: Niraparib and Abiraterone Acetate ...
ESMO 2025: Biomarker Analyses from the Phase II PT-112 Monotherapy ...
ESMO 2025: Invited Discussant - Perioperative Immunotherapy Strategies ...
ESMO 2022: Biomarker Analysis and Updated Results from the Phase III ...
ESMO 2025: Discussant: Precision in the Adjuvant Gap – IMvigor011 and ...
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone ...
ESMO 2025: Discussant: Lymphocyte Activation Gene-3 (LAG3) Expression ...
ESMO 2025: Invited Discussant: KEYMAKER-UO3 Substudy 03A, LenCabo ...
ESMO 2025: Exploiting Homologous Recombination Alteration Across the ...
ESMO 2025: Discussion: Long-Term SAKK 01/10 Seminoma Outcomes and the ...
MATTERHORN Trial at ESMO 2025: Durvalumab Plus FLOT in Resectable ...
ASCO 2026: XALience: A Phase 3, Open-Label, Multicenter, Randomized ...
316P Capivasertib (C) + ribociclib (R) + fulvestrant (F) in patients ...
ESMO 2024: Efficacy and Safety of Darolutamide plus ADT in Patients ...
Capivasertib + Abiraterone for Prostate Cancer Clinical Trial 2024 | Power
BriaCell Unveils Promising Phase 3 Biomarkers at ESMO 2025 - Investors ...
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter ...
ESMO 2024: Invited Discussant: Phase 3 ARANOTE Trial, Phase 3 ...
CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ...
ESMO 2025 Highlights in Non-muscle-Invasive Bladder Cancer - European ...
Florian Lordick: Matterhorn Study Reports Overall Survival Outcomes in ...
ESMO 2025 Iza-Bren (BL-B01D1), an EGFR×HER3 Bispecific Antibody-drug ...
ESMO 2025: Invited Discussant: mHSPC in 2025: More, Less, or Smarter?
Capivasertib and fulvestrant for patients with hormone receptor ...
Top 10 Immunotherapy Trials in Lung Cancer to Watch at ESMO 2025 ...
New Results And Forthcoming Trials Presented At ESMO 2025 Underline ...
ASCO 2025: Mevrometostat in Combination with Enzalutamide in Patients ...
#ESMOAI25: Global experts on why you should attend the new ESMO AI ...
Capivasertib and fulvestrant for patients with HR-positive/HER2 ...
European Society for Medical Oncology (ESMO) Congress 2024 – Poster ...
Precision in Prostate Cancer: Germline vs Somatic Testing and Treatment ...
DYNAMIC-III: ctDNA-Guided Chemotherapy in Stage III CC
Everything You Need to Know About Immunotherapy at ESMO 2025 - OncoDaily
ESMO Congress 2025
ESMO 2025 - The Grand Catch-Up (Berlin, October 17-21, 2025) - OncoDaily
Top Upper GI Cancer Trials to Watch at ESMO 2025 - OncoDaily
KEYNOTE-905: EV + Pembrolizumab Boosts Survival in MIBC
Copyright © 2010, Research To Practice, All rights reserved. Part VIII ...
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
ANAVEON | Anaveon announces poster presentation at the 2025 European ...
Retour sur l’ESMO 2025 - Centre François Baclesse
Read News and Stories about NANETS 2025 - Oncodaily
